Navigation Links
EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology
Date:9/25/2017

PROVIDENCE, R.I., Sept. 25, 2017 /PRNewswire/ -- EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided exclusive access to enabling technologies to the new precision immunotherapy venture. Gad Berdugo MSc Eng., MBA will lead EpiVax Oncology as Chief Executive Officer. Gad brings over 25 years of biotechnology operational, strategic partnering and financial experience gained at Abbott, Baxter, and Lazard, as well as emerging cancer biotechnology companies.

EpiVax Oncology's approach to precision immunotherapy is based on mutated, tumor-specific epitopes, termed Neo-Epitopes, which generate highly potent specific T cell responses against a wide range of tumor types. The company uses genetic profiling (via NGS sequencing) to generate therapeutic vaccines customized for each cancer patient's unique tumor load. EpiVax Oncology vaccines can be used in combination with checkpoint inhibitors or potentially as single agents.

EpiVax Oncology's key competitive advantage is centered on a streamlined, validated, commercial-grade Neo-Epitope in silico discovery platform called Ancer™. The Ancer™ platform is powered by EpiVax's EpiMatrix™ and JanusMatrix™ predictive algorithms and exclusively licensed to EpiVax Oncology for the field of cancer. Ancer™ identifies highly immunogenic, Class I and Class II, CD4 and CD8, T cell Neo-Epitopes while selecting out Treg-like epitopes. Candidate Neo-epitopes are qualified and ranked using a proprietary process designed to strengthen vaccine efficacy and decrease the incidence of immune-related adverse events. In head-to-head comparisons, Ancer™ is significantly better at Neo-Epitope identification than public or academic platforms.

"Ancer™ is setting EpiVax Oncology apart from emerging companies such as Neon Therapeutics, Gritstone Oncology and BioNtech. EpiVax Oncology will leverage EpiVax's world class excellence in computational immunology, genomics and vaccine design, built over the last 20 years, to create safe, effective, and affordable immunotherapies. We are committed to delivering on the promise of precision medicine," said Gad Berdugo.

CLINICAL DEVELOPMENT: EpiVax Oncology is initially preparing for Phase 1b clinical trials in bladder cancer and melanoma using Ancer™-derived Neo-Epitopes formulated in a proprietary clinically-tested delivery vehicle. The first trials are planned to start in 2018.

CAPITAL RAISE: EpiVax Oncology is a fully independent company currently conducting a $2M bridge capital raise to prepare for an IND as well as a $10M to $25M Series A financing to fund the first-in-man clinical trials.

ABOUT EPIVAX: EpiVax, Inc. is a privately-held biotechnology company focused on the development of vaccines and immunotherapies mainly for infectious diseases and autoimmunity. Led by Annie S. De Groot, M.D., an internationally recognized vaccine design thought leader, and William Martin, chief architect of the EpiMatrix Epitope Discovery Platform, EpiVax has enjoyed significant success in the fields of immunology and bioinformatics.

http://www.EpiVax.com
http://www.EpiVaxOnco.com

Media Contacts:
Gad Berdugo
EpiVax Oncology
gberdugo@epivaxonco.com
+1 (646) 912-2525

Anne S. De Groot MD
EpiVax
AnnieD@EpiVax.com
+1 (401) 952-4227

View original content with multimedia:http://www.prnewswire.com/news-releases/epivax-launches-precision-cancer-immunotherapy-venture-epivax-oncology-300525002.html


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. EpiVax Reports $5.2 Million for New Q Fever Vaccine Means There is Hope for Vaccines On Demand
2. EpiVax: Investition von 5,2 Millionen $ in neuen Impfstoff für Q-Fieber bedeutet Hoffnung für Impfstoffe auf Abruf
3. $5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax
4. X-Change Corporation Launches Upgraded Version of Phytiva Website, As Company Targets Distribution of Phytiva Product Line in United States and Worldwide, Extracts and New Products in Europe
5. PENTAX Medical Launches Industrys Highest* Resolution HD+ Imaging Technology For Flexible Endoscopy
6. Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices
7. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
8. WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile
9. Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site
10. Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services
11. TMA Launches Physician Services Organization for Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2019)... ... 21, 2019 , ... Lantana Consulting Group, Inc. is pleased ... HL7® FHIR® implementation guides (IGs) and one of the first FHIR tools to ... with which 1,350 users have authored over 200 CDA® IGs. Both versions of ...
(Date:1/21/2019)... ... January 21, 2019 , ... Why do people spend countless hours stressing over ... Worry Work and What to Do to Overcome Them” (published by AuthorHouse UK), psychologist ... provides the tools to stop overthinking. , “So many of us spend months ...
(Date:1/20/2019)... ... January 18, 2019 , ... The Icahn School of ... drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS), with Australia-based company ... , MPS is a group of 11 lysosomal storage diseases, metabolic disorders caused ...
Breaking Medicine Technology:
(Date:1/20/2019)... ... 18, 2019 , ... Dr. Faye Jamali, a board-certified physician ... state-of-the-art medical boutique, Belle Marin Aesthetic Medicine, with a grand opening event on ... will enjoy refreshments, prize drawings, and exclusive event-only pricing. Attendees will meet the ...
(Date:1/15/2019)... ... January 15, 2019 , ... Dr. James Petros, Medical Director ... of yet another office location for the thriving practice, which is located at 100 ... to open in mid-February and will offer the same comprehensive menu of pain management ...
(Date:1/14/2019)... ... January 14, 2019 , ... After many months of preparation, ... clinic in Phoenix, Arcadia Allergy & Asthma. This new allergy and asthma clinic is ... a great one stop destination for any immunological and respiratory medical care needs. , ...
(Date:1/14/2019)... , ... January 14, 2019 , ... ... supplements, household and personal-care products with a presence worldwide, today announced that it ... 2018. Measured year-over-year, Modere sales grew by double-digits in North America, by more ...
(Date:1/14/2019)... ... 14, 2019 , ... The Centers for Disease Control (CDC) ... Zoster Immune Globulin [Human]) for post-exposure prophylaxis of varicella in patients at high-risk, ... that VARIZIG is commercially available from a broad network of specialty distributors in ...
Breaking Medicine News(10 mins):